Commercial Due Diligence as a decision-making framework under uncertainty

Why Storytelling Is Not a Basis for Decision-Making

Storytelling links individual assumptions into a plausible trajectory. Market size leads to revenue, clinical success to market access, differentiation to growth. For investors, this linearity is not decisive. What interests them above all is where this chain breaks down.

Every story is based on assumptions. Diagnostic rates, comparator therapies, price levels, or adoption are not facts, but hypotheses with uncertainties. As long as these assumptions are not made explicit, it remains unclear how robust a business case is.

It is not the quality of the story that decides, but the transparency of the underlying assumptions.

The Real Subject of Assessment: Uncertainty

A business case is often understood as a tool for determining a value. In practice, it describes a system of assumptions under uncertainty. Investors therefore assess not a single number, but the range of possible developments.

The key question is not whether a scenario can occur, but how likely it is and what impact it has. A successful clinical trial outcome, a new competitor, or a changed reimbursement decision are not peripheral conditions. They are central drivers of the valuation.

The value of a company does not arise from a single scenario, but from the distribution of possible developments.

From Assumptions to Risk Structures

The crucial step in commercial due diligence is to structure assumptions systematically. It becomes clear that risks rarely occur in isolation. They arise at the interfaces of clinical practice, access, and utilization.

Clinical effectiveness alone is not sufficient if the added benefit compared with the standard therapy is not recognized. A high price is not achievable if the added benefit compared with the standard therapy is not recognized. A high price is not achievable if budget constraints apply. A large target population remains theoretical if diagnostics and care are limited. This linkage creates a risk structure that is far more complex than individual assumptions.

Risk structure means making dependencies visible, not just assessing variables. 

Which Assumptions Actually Drive Value

Not all assumptions have the same impact on value. This is exactly where a key misconception lies. Obvious parameters such as price or market size are often overestimated. At the same time, structural drivers such as diagnostic rates, access barriers, or care pathways remain underestimated.

A sound analysis shows which assumptions have the greatest impact on value and which changes are actually decision-relevant. Often, small changes in central parameters have a greater effect than seemingly significant adjustments elsewhere.

Value is determined by the most sensitive assumptions, not by the most visible ones.

Decision Logic Under Uncertainty

In the end, the goal is not to calculate a value as precisely as possible. What matters is how the value behaves under different conditions. 

Investors think in scenarios and events. They ask how value changes when key assumptions do not materialize or develop differently than expected. This perspective makes it possible to prioritize and address risks in a targeted way. At the same time, it becomes clear where uncertainty is manageable and where structural risks remain. 

Commercial due diligence therefore does not deliver a forecast, but a robust decision-making framework. The difference lies not in the precision of a model, but in the ability to assess uncertainty in a structured way.

Conclusion

Risk structure instead of storytelling describes a fundamental shift in perspective in the assessment of life science business models. 

Narratives are suitable for sparking interest. They are not sufficient for investment decisions. Only through the systematic analysis of assumptions, their interdependencies, and their effects does a robust basis for decision-making emerge. The focus thus shifts from presenting potential to assessing uncertainty and its impact on value.

About Excellere LifeScience Consulting

In practice, we often see business cases that appear consistent but do not adequately reveal key risks. Assumptions are formulated, but their impact on overall value is not analyzed.

Our approach in commercial due diligence is to systematically translate business models into their risk structure. In doing so, we identify the key value drivers, analyze their interdependencies, and make the effects of uncertainty transparent.

We do not assess markets; we analyze which assumptions drive value and how sensitive it is to uncertainty. The goal is not only to provide a picture of potential, but to create a robust basis for decision-making under uncertainty.